Relay Therapeutics (RLAY) Competitors $2.69 +0.08 (+3.07%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.68 -0.02 (-0.56%) As of 04/17/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLAY vs. IRON, TVTX, SDGR, IDYA, MESO, IMCR, INDV, CGON, VERA, and SPRYShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Disc Medicine (IRON), Travere Therapeutics (TVTX), Schrödinger (SDGR), IDEAYA Biosciences (IDYA), Mesoblast (MESO), Immunocore (IMCR), Indivior (INDV), CG Oncology (CGON), Vera Therapeutics (VERA), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. Disc Medicine Travere Therapeutics Schrödinger IDEAYA Biosciences Mesoblast Immunocore Indivior CG Oncology Vera Therapeutics ARS Pharmaceuticals Disc Medicine (NASDAQ:IRON) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings. Does the MarketBeat Community favor IRON or RLAY? Relay Therapeutics received 4 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 86.57% of users gave Disc Medicine an outperform vote while only 69.66% of users gave Relay Therapeutics an outperform vote. CompanyUnderperformOutperformDisc MedicineOutperform Votes5886.57% Underperform Votes913.43%Relay TherapeuticsOutperform Votes6269.66% Underperform Votes2730.34% Does the media prefer IRON or RLAY? In the previous week, Relay Therapeutics had 1 more articles in the media than Disc Medicine. MarketBeat recorded 5 mentions for Relay Therapeutics and 4 mentions for Disc Medicine. Relay Therapeutics' average media sentiment score of 0.83 beat Disc Medicine's score of 0.76 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do insiders and institutionals believe in IRON or RLAY? 83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 4.2% of Disc Medicine shares are owned by insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer IRON or RLAY? Disc Medicine currently has a consensus price target of $93.80, suggesting a potential upside of 122.43%. Relay Therapeutics has a consensus price target of $18.36, suggesting a potential upside of 582.66%. Given Relay Therapeutics' higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82 Is IRON or RLAY more profitable? Disc Medicine's return on equity of -25.24% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -25.24% -23.96% Relay Therapeutics N/A -45.75%-40.75% Which has more risk and volatility, IRON or RLAY? Disc Medicine has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Which has higher earnings & valuation, IRON or RLAY? Disc Medicine has higher earnings, but lower revenue than Relay Therapeutics. Disc Medicine is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$76.43M-$3.99-10.57Relay Therapeutics$10.01M45.57-$341.97M-$2.39-1.13 SummaryRelay Therapeutics beats Disc Medicine on 10 of the 17 factors compared between the two stocks. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$456.01M$2.84B$5.29B$7.35BDividend YieldN/A1.90%5.11%4.31%P/E Ratio-1.0330.4821.7117.77Price / Sales45.57441.91379.1097.68Price / CashN/A168.6838.1534.64Price / Book0.463.466.433.98Net Income-$341.97M-$72.06M$3.21B$247.44M7 Day Performance21.17%6.38%5.23%4.44%1 Month Performance-23.36%-17.51%-9.53%-7.73%1 Year Performance-56.68%-27.84%10.95%1.28% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics2.713 of 5 stars$2.69+3.1%$18.36+582.7%-56.7%$456.01M$10.01M-1.03330Analyst ForecastNews CoveragePositive NewsGap UpIRONDisc Medicine2.416 of 5 stars$39.20-4.9%$93.80+139.3%+39.3%$1.36BN/A-9.8530High Trading VolumeTVTXTravere Therapeutics2.5969 of 5 stars$15.17+1.2%$31.46+107.4%+149.1%$1.35B$233.18M-3.70460Gap UpSDGRSchrödinger2.5326 of 5 stars$18.21+1.0%$32.29+77.3%+2.8%$1.33B$207.54M-7.78790Analyst ForecastInsider TradeNews CoverageIDYAIDEAYA Biosciences3.5552 of 5 stars$15.14+2.9%$53.58+253.9%-57.5%$1.33B$7M-4.5980Positive NewsGap UpHigh Trading VolumeMESOMesoblast2.4067 of 5 stars$10.40-1.6%$18.00+73.1%+114.0%$1.32B$5.67M0.0080Positive NewsGap UpIMCRImmunocore2.3765 of 5 stars$26.28-3.6%$65.18+148.0%-47.9%$1.31B$310.20M-27.66320Analyst ForecastGap DownINDVIndivior3.7496 of 5 stars$9.39+2.6%$15.00+59.7%-53.2%$1.29B$1.19B-26.831,164Upcoming EarningsShort Interest ↓Positive NewsCGONCG Oncology1.109 of 5 stars$16.92-1.6%$63.88+277.5%-43.3%$1.29B$1.14M-11.9261Analyst ForecastGap DownHigh Trading VolumeVERAVera Therapeutics2.897 of 5 stars$19.94-6.4%$64.67+224.3%-46.8%$1.27BN/A-7.6440Gap UpHigh Trading VolumeSPRYARS Pharmaceuticals3.0959 of 5 stars$12.83+0.2%$31.00+141.6%+64.2%$1.26B$89.15M-25.1690Gap UpHigh Trading Volume Related Companies and Tools Related Companies IRON Alternatives TVTX Alternatives SDGR Alternatives IDYA Alternatives MESO Alternatives IMCR Alternatives INDV Alternatives CGON Alternatives VERA Alternatives SPRY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLAY) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RLAY Stock Free RLAY Stock Alerts